High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis

Emanuele Nicastri, Loredana Sarmati, Gabriella D'Ettorre, Saverio G. Parisi, Lucia Palmisano, Clementina Galluzzo, Marco Montano, Ilaria Uccella, Roberta Amici, Francesca Gatti, Vincenzo Vullo, Ercole Concia, Stefano Vella, Massimo Andreoni

Research output: Contribution to journalArticle

Abstract

Whether highly active antiretroviral therapy (HAART) should be modified in patients with persistent increases in CD4+ T cells despite detectable viral loads is an unresolved question. Forty-three heavily pretreated human immunodeficiency virus (HIV)-infected patients with virologic failure during HAART were studied before a change of therapy guided by genotypic analysis and during follow-up. Patients with an increase in CD4+ cell count (>100 cells/ml) over pre-HAART values were considered to be discordant patients (20 individuals), whereas patients with a lower increase or no increase in CD4+ cell count were considered failing patients (23 individuals). Based on univariate analysis, a high CD4+ cell count before antiretroviral treatment, homosexual behavior as a risk factor for HIV infection, reduced drug exposure to nonnucleoside reverse transcriptase inhibitors, low replicative capacity of HIV isolates, and more frequent detection of HIV isolates with a non-B subtype, an R5 biological phenotype, and M184V and T215Y/F mutations were factors associated with a discordant response to HAART. Based on multivariate analysis, only the M184V mutation remained significantly associated with a viroimmunologic discordant response (odds ratio, 25.48; 95% confidence interval, 1.43 to 453.93). No difference in lamivudine exposure was found between discordant (95%) and failing (91%) patients. Twelve months after the genotypic analysis-guided change of therapy, 3 discordant (15%) and 6 failing patients (26%) achieved undetectable viral loads (500 copies/mi, discordant responses were observed in 5 out of 15 discordant patients and in 4 out of 16 failing patients. A relationship between the M184V mutation and a viroimmunologic discordant response to HAART was found. After the genotypic analysis-driven change of therapy, similar rates of virologic suppression were detected in the two groups.

Original languageEnglish
Pages (from-to)3007-3012
Number of pages6
JournalJournal of Clinical Microbiology
Volume41
Issue number7
DOIs
Publication statusPublished - Jul 1 2003

Fingerprint

Highly Active Antiretroviral Therapy
Mutation
CD4 Lymphocyte Count
HIV
Therapeutics
Viral Load
Reverse Transcriptase Inhibitors
Lamivudine
Virus Diseases
Multivariate Analysis
Odds Ratio
Confidence Intervals
T-Lymphocytes
Phenotype

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. / Nicastri, Emanuele; Sarmati, Loredana; D'Ettorre, Gabriella; Parisi, Saverio G.; Palmisano, Lucia; Galluzzo, Clementina; Montano, Marco; Uccella, Ilaria; Amici, Roberta; Gatti, Francesca; Vullo, Vincenzo; Concia, Ercole; Vella, Stefano; Andreoni, Massimo.

In: Journal of Clinical Microbiology, Vol. 41, No. 7, 01.07.2003, p. 3007-3012.

Research output: Contribution to journalArticle

Nicastri, E, Sarmati, L, D'Ettorre, G, Parisi, SG, Palmisano, L, Galluzzo, C, Montano, M, Uccella, I, Amici, R, Gatti, F, Vullo, V, Concia, E, Vella, S & Andreoni, M 2003, 'High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis', Journal of Clinical Microbiology, vol. 41, no. 7, pp. 3007-3012. https://doi.org/10.1128/JCM.41.7.3007-3012.2003
Nicastri, Emanuele ; Sarmati, Loredana ; D'Ettorre, Gabriella ; Parisi, Saverio G. ; Palmisano, Lucia ; Galluzzo, Clementina ; Montano, Marco ; Uccella, Ilaria ; Amici, Roberta ; Gatti, Francesca ; Vullo, Vincenzo ; Concia, Ercole ; Vella, Stefano ; Andreoni, Massimo. / High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. In: Journal of Clinical Microbiology. 2003 ; Vol. 41, No. 7. pp. 3007-3012.
@article{a97eee60a16945bf8fbbbd38087e6d5c,
title = "High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis",
abstract = "Whether highly active antiretroviral therapy (HAART) should be modified in patients with persistent increases in CD4+ T cells despite detectable viral loads is an unresolved question. Forty-three heavily pretreated human immunodeficiency virus (HIV)-infected patients with virologic failure during HAART were studied before a change of therapy guided by genotypic analysis and during follow-up. Patients with an increase in CD4+ cell count (>100 cells/ml) over pre-HAART values were considered to be discordant patients (20 individuals), whereas patients with a lower increase or no increase in CD4+ cell count were considered failing patients (23 individuals). Based on univariate analysis, a high CD4+ cell count before antiretroviral treatment, homosexual behavior as a risk factor for HIV infection, reduced drug exposure to nonnucleoside reverse transcriptase inhibitors, low replicative capacity of HIV isolates, and more frequent detection of HIV isolates with a non-B subtype, an R5 biological phenotype, and M184V and T215Y/F mutations were factors associated with a discordant response to HAART. Based on multivariate analysis, only the M184V mutation remained significantly associated with a viroimmunologic discordant response (odds ratio, 25.48; 95{\%} confidence interval, 1.43 to 453.93). No difference in lamivudine exposure was found between discordant (95{\%}) and failing (91{\%}) patients. Twelve months after the genotypic analysis-guided change of therapy, 3 discordant (15{\%}) and 6 failing patients (26{\%}) achieved undetectable viral loads (500 copies/mi, discordant responses were observed in 5 out of 15 discordant patients and in 4 out of 16 failing patients. A relationship between the M184V mutation and a viroimmunologic discordant response to HAART was found. After the genotypic analysis-driven change of therapy, similar rates of virologic suppression were detected in the two groups.",
author = "Emanuele Nicastri and Loredana Sarmati and Gabriella D'Ettorre and Parisi, {Saverio G.} and Lucia Palmisano and Clementina Galluzzo and Marco Montano and Ilaria Uccella and Roberta Amici and Francesca Gatti and Vincenzo Vullo and Ercole Concia and Stefano Vella and Massimo Andreoni",
year = "2003",
month = "7",
day = "1",
doi = "10.1128/JCM.41.7.3007-3012.2003",
language = "English",
volume = "41",
pages = "3007--3012",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis

AU - Nicastri, Emanuele

AU - Sarmati, Loredana

AU - D'Ettorre, Gabriella

AU - Parisi, Saverio G.

AU - Palmisano, Lucia

AU - Galluzzo, Clementina

AU - Montano, Marco

AU - Uccella, Ilaria

AU - Amici, Roberta

AU - Gatti, Francesca

AU - Vullo, Vincenzo

AU - Concia, Ercole

AU - Vella, Stefano

AU - Andreoni, Massimo

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Whether highly active antiretroviral therapy (HAART) should be modified in patients with persistent increases in CD4+ T cells despite detectable viral loads is an unresolved question. Forty-three heavily pretreated human immunodeficiency virus (HIV)-infected patients with virologic failure during HAART were studied before a change of therapy guided by genotypic analysis and during follow-up. Patients with an increase in CD4+ cell count (>100 cells/ml) over pre-HAART values were considered to be discordant patients (20 individuals), whereas patients with a lower increase or no increase in CD4+ cell count were considered failing patients (23 individuals). Based on univariate analysis, a high CD4+ cell count before antiretroviral treatment, homosexual behavior as a risk factor for HIV infection, reduced drug exposure to nonnucleoside reverse transcriptase inhibitors, low replicative capacity of HIV isolates, and more frequent detection of HIV isolates with a non-B subtype, an R5 biological phenotype, and M184V and T215Y/F mutations were factors associated with a discordant response to HAART. Based on multivariate analysis, only the M184V mutation remained significantly associated with a viroimmunologic discordant response (odds ratio, 25.48; 95% confidence interval, 1.43 to 453.93). No difference in lamivudine exposure was found between discordant (95%) and failing (91%) patients. Twelve months after the genotypic analysis-guided change of therapy, 3 discordant (15%) and 6 failing patients (26%) achieved undetectable viral loads (500 copies/mi, discordant responses were observed in 5 out of 15 discordant patients and in 4 out of 16 failing patients. A relationship between the M184V mutation and a viroimmunologic discordant response to HAART was found. After the genotypic analysis-driven change of therapy, similar rates of virologic suppression were detected in the two groups.

AB - Whether highly active antiretroviral therapy (HAART) should be modified in patients with persistent increases in CD4+ T cells despite detectable viral loads is an unresolved question. Forty-three heavily pretreated human immunodeficiency virus (HIV)-infected patients with virologic failure during HAART were studied before a change of therapy guided by genotypic analysis and during follow-up. Patients with an increase in CD4+ cell count (>100 cells/ml) over pre-HAART values were considered to be discordant patients (20 individuals), whereas patients with a lower increase or no increase in CD4+ cell count were considered failing patients (23 individuals). Based on univariate analysis, a high CD4+ cell count before antiretroviral treatment, homosexual behavior as a risk factor for HIV infection, reduced drug exposure to nonnucleoside reverse transcriptase inhibitors, low replicative capacity of HIV isolates, and more frequent detection of HIV isolates with a non-B subtype, an R5 biological phenotype, and M184V and T215Y/F mutations were factors associated with a discordant response to HAART. Based on multivariate analysis, only the M184V mutation remained significantly associated with a viroimmunologic discordant response (odds ratio, 25.48; 95% confidence interval, 1.43 to 453.93). No difference in lamivudine exposure was found between discordant (95%) and failing (91%) patients. Twelve months after the genotypic analysis-guided change of therapy, 3 discordant (15%) and 6 failing patients (26%) achieved undetectable viral loads (500 copies/mi, discordant responses were observed in 5 out of 15 discordant patients and in 4 out of 16 failing patients. A relationship between the M184V mutation and a viroimmunologic discordant response to HAART was found. After the genotypic analysis-driven change of therapy, similar rates of virologic suppression were detected in the two groups.

UR - http://www.scopus.com/inward/record.url?scp=0038506985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038506985&partnerID=8YFLogxK

U2 - 10.1128/JCM.41.7.3007-3012.2003

DO - 10.1128/JCM.41.7.3007-3012.2003

M3 - Article

C2 - 12843034

AN - SCOPUS:0038506985

VL - 41

SP - 3007

EP - 3012

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 7

ER -